| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
NEWS |
Human Cancer Genome Project Moving Forward Despite Some Doubts in Community
| The first 150 words of the full text of this article appear below. |
The Human Cancer Genome Project, a proposed 10-year, $1.5 billion effort to achieve "a comprehensive genomic analysis of cancer," is preparing to launch its 3-year pilot project as soon as next year. But some disagreement remains about how best to dissect the genetics of cancer and ultimately find cures. And although the project's planners intend to seek new funding for the main project and not put investigator-initiated grants at risk, some cancer researchers are worried that the project will indirectly depress available funds.
The goal of the genome project is to identify all the functional gene mutations and other abnormalities in common tumor types. Once accomplished, this information could lead to more individualized drug therapy and the development of drugs against newly discovered targets. "We know cancer is a genetic disease, and I think it's a very worthwhile investment to find all the genetic alterations that occur in major cancer
Linking Mutations to Drugs
A Worrisome Precedent?
A Functional Alternative?
The Case for Big Science
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. W. Foster, J. J. Mulvihill, and R. R. Sharp Investments in Cancer Genomics: Who Benefits and Who Decides Am J Public Health, November 1, 2006; 96(11): 1960 - 1964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Foster and R. R. Sharp Ethical issues in medical-sequencing research: implications of genotype-phenotype studies for individuals and populations. Hum. Mol. Genet., April 15, 2006; 15(suppl_1): R45 - R49. [Abstract] [Full Text] [PDF]
|
|